GlassScriptPhysician profile
Timur Gusov
NPI 1144633868
$4,967.90
in general payments reported to CMS, 2019-2025
37 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.73 · 2022: $726 · 2023: $1,492 · 2024: $1,436 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260 · Travel and Lodging: $886 · Entertainment: $16.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.46 |
| Travel and Lodging | $886.03 |
| Entertainment | $16.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,187.13 | 2023-2025 | Minimed 780g |
| Amgen INC. | $388.64 | 2022-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $387.75 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $353.58 | 2022-2024 | |
| Lilly USA, LLC | $330.05 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $293.69 | 2022-2024 | |
| Abbott Laboratories | $261.47 | 2022-2024 | Freestyle Libre 3 |
| Radius Health, INC. | $213.97 | 2022-2024 | Tymlos |
| Dexcom, INC. | $144.18 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.07 | 2022-2024 | Jardiance |
| Nevro Corp. | $114.74 | 2022-2023 | Senza |
| Merck Sharp & Dohme LLC | $110.70 | 2023-2024 | Zerbaxa, Recarbrio, Dificid |
| Ascensia Diabetes Care US INC. | $109.08 | 2022-2025 | |
| Cequr Corporation | $91.28 | 2023-2024 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $68.76 | 2023-2024 | Farxiga |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $66.62 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.99 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $62.43 | 2023-2024 | Isturisa, Signifor Lar |
| Aimmune Therapeutics, INC. | $60.78 | 2024 | |
| Insulet Corporation | $50.86 | 2025 | Omnipod |
| Corcept Therapeutics | $49.22 | 2024 | Korlym |
| Averitas Pharma INC. | $48.76 | 2023 | Qutenza |
| Paratek Pharmaceuticals, INC. | $43.01 | 2024 | Nuzyra |
| Melinta Therapeutics, LLC | $36.10 | 2022-2023 | Kimyrsa, Vabomere |
| Tandem Diabetes Care, INC. | $34.98 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $34.96 | 2023 | Gvoke Hypopen |
| Kyowa Kirin, INC. | $34.03 | 2023 | Crysvita |
| Organogenesis INC. | $27.44 | 2022-2023 | Puraply |
| Janssen Biotech, INC. | $23.19 | 2022 | |
| Shionogi INC | $21.20 | 2024 | Fetroja |
| Viiv Healthcare Company | $21.10 | 2024 | Apretude |
| Chiesi USA, INC. | $19.92 | 2024 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $18.02 | 2023 | |
| Halozyme INC | $17.55 | 2023 | |
| Optos, INC. | $16.07 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Rhythm Pharmaceuticals, INC. | $14.18 | 2023 | Imcivree |
| Amneal Pharmaceuticals LLC | $13.40 | 2024 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timur Gusov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.